The Administration still maintains broad authority to manage the implementation of the No Surprises Act even in a ...

Policy makers serve an important role in overseeing private equity’s ownership of clinics and hospitals. State-based policies ...

The time is now to align on a shared plan of action as a country to achieve diversity, equity, inclusion, and access in US ...

The policies proposed by Project 2025, if implemented, could fundamentally reshape not only the landscape of reproductive ...

As our nation ages, with the need to address more mental health and loneliness challenges than ever, it is time to design new ...

The sweeping relief sought by plaintiffs could erode protections for consumers against unanticipated financial liabilities ...

On September 30, a federal district judge in Florida held for the first time that lawsuits initiated by whistleblowers under the False Claims Act are unconstitutional, dismissing a Medicare fraud case ...

Regulation of health system consolidation should take into account all aspects of the market for health care goods and ...

Identification Of High-Veteran MA Plans For each year between 2016 and 2022, we defined high-veteran MA plans as MA plans with VHA enrollees exceeding 20 percent of their total enrollment, which ...

Biosimilars present a key opportunity to contain the growing cost of biologic drug spending and to make essential medications more affordable. However, the lackluster performance of the US biosimilar ...

The NIH’s current system for funding scientific research perpetuates health disparities by privileging established, well-resourced institutions and reinforcing an individual-level focus on disease ...

Health Affairs' Editor-in-Chief Alan Weil interviews Janice Jhang of Harvard University about her recent paper that explores how regulatory and market forces are driving adoption of biosimilars.